肾细胞癌血管生成与癌细胞转移的关系

目的：探讨肾细胞癌血管生成及其与肿瘤转移的关系。方法：采用免疫组织化学ＬＳＡＢ法检测肾细胞癌血管内皮生长因子（ＶＥＧＦ）的表达及微血管数（ＭＶＣ）。结果：癌组织中ＶＥＧＦ的表达与ＭＶＣ有关;有肿瘤转移者ＶＥＧＦ表达和ＭＶＣ的等级分布显著高于无肿瘤转移者。结论：肾细胞癌血管生成可能有赖于癌细胞合成分泌的ＶＥＧＦ来调节;ＶＥＧＦ表达和ＭＶＣ均与肿瘤转移有关,有可能作为判断肾细胞癌转移潜能的预后指标。     

1α,25—二羟维生素D3对前列腺癌LNCaP细胞中E—cadherin调？…

为探讨１α２５－二羟维生素Ｄ３与前列腺癌转移之间的关系，采用ＷｅｓｔｅｒｎＢｌｏｔ印迹及免疫荧光法分析了前列腺癌细胞株ＬＮＣａＰ细胞中Ｅ－ｃａｄｈｅｒｉｎ的表达，用逆转录聚合酶链反应分析了Ｅ－ｃａｄｈｅｒｉｎｍＲＮＡ的表达。结果当培养液中加入０．０１、０．１和１．０ｎｍｏｌ／Ｌ浓度的１α，２５－二羟生素Ｄ３时，ＬＮＣａＰ细胞中Ｅ－＝ｃａｄｈｅｒｉｎ表达增强，当浓度增加到１０和１００ｎｍｏｌ／Ｌ时，     

逆转录病毒介导HyTK基因治疗膀胱癌的实验研究

目的 了解逆洋病毒介导的潮霉素磷酸转移酶和ＨＳＶ－ＴＫ的融合基因（ＨｙＴＫ）的基因转移移联合更昔洛韦（ＧＣＶ）对膀胱癌细胞的杀伤作用。方法 构建重组质粒ＰＬ（ＨｙＴＫ）ＳＮ,应用非脂质体基因转导系统ＦｕＧＥＮＥ＾ＴＭ６及“乒乓效应”（ｐｉｎｇ－ｐｏｎｇ ｍｅｃｈａｎｉｓｍ）,获 滴度重组病毒并转染膀胱朱ＥＪ／ＨｙＴＫ的杀伤作用。结果 本文实验逆转录病毒的效率为３５％左右,Ｓｏｕｔｈｅｍ Ｂｌｏｔ、     

碱性成纤维细胞生长因子是预测肝细胞癌根治性切除术后转移复发的潜在指标

由于碱性成纤维细胞生长因子(ｂＦＧＦ)在肿瘤血管生成中发挥重要作用 ,从而参与肿瘤的转移复发。血清ｂＦＧＦ水平升高可能是一个潜在预测肿瘤转移复发的生物学标志。一、资料和方法1.临床资料 :ＣＯＸ风险模型资料来源于 1990至 1997年入院行肝部分切除术并经术后病理确诊为ＨＣＣ且术前术后均未接受任何形式抗癌治疗的患者(193例 )。检测的 72例术前血清及 2 4例对应ＨＣＣ组织标本来源于 1998年 5月至 1998年 11月收治手术并经病理证实为ＨＣＣ且术前均未接受任何形式抗癌治疗的患者。血清均从手术前ＨＣＣ患者外周血分离 ,- 80℃放置备…     

肝细胞肝癌中血管内皮生长因子及其受体表达的意义及p5 …

目的 探讨ＶＥＧＦ及其受体ＫＤＲ在肝细胞肝癌（ＨＣＣ）的血管生成、生长及转移中的作用及Ｐ５３、ｒａｓ对ＶＥＧＦ表达的调控。方法 用免疫组织化学、原位杂交图像分析的方法研究肝细胞肝癌４５例、肝硬化２１例及正常肝８例的石蜡标本切片，从而探讨ＶＥＧＦ、ＫＤ直癌病理学特点的关系及Ｐ５３、ｒａｓ对其表达的影响。结果 肝癌组中ＶＥＧＦ的表达明显闹于肝硬化组和正常肝组，３组的表达率分别为６４％（２９／４５）、１     

先天性心脏病合并肺动脉高压患儿血清血管内皮生长因子含量的变化

目的 观察先天性心脏病（ＣＨＤ）合并肺动脉高压（ＰＨ）患儿肺动,静脉血清血管内皮生长因子（ＶＥＧＦ）的含量并探讨其与ＣＨＤ引起ＰＨ间的关系,方法 应用双抗体夹心酶联免疫吸附法（ＥＬＩＳＡ）检测ＣＨＤ合并ＰＨ（ＰＨ组）以及不合并ＰＨ（对照组）患儿肺动,静脉血清ＶＥＧＦ的含量的。结果（１）ＰＨ组患儿肺动脉血清ＶＥＧＦ含量与对照组无有显差异（Ｐ〉０．０５０,而肺静脉血清ＶＥＧＦ含量明显高于对照组（Ｐ〈０     

骨巨细胞瘤GCF－5抗原分子量测定及蛋白性质分析

为了探明抗骨巨细胞瘤（ＧＣＴ）肿瘤细胞成分的单克隆抗体ＧＣＦ－５相应抗原的性质，并为研究ＧＣＴ肿瘤抗原打下基础。本研究采用高浓度ＳＤＳ提取细胞膜蛋白。用ＳＤＳ－ＰＡＧＥ，ＷｅｓｔｅｒｎＢｌｏｔｉｎｇ分析了抗原蛋白的分子量。用蛋白质化学染色技术对ＧＣＦ－５抗原蛋白进行了糖、脂分类染色。结果显示主要的ＧＣＦ－５抗原为分子量１３．５ＫＤ和１７．４ＫＤ的含糖量极少的糖蛋白     

PGE2和IL-2/IL-2R 在胃癌患者手术前后的动态变化和相互关系

目的　探讨胃癌患者外周血中白细胞介素２ （ＩＬ２）、白细胞介素２ 受体（ｓＩＬ２Ｒ） 水平及ＣＤ２５ 表达三者手术前后的动态变化情况和相互关系,以及前列腺素Ｅ２（ＰＧＥ２） 与ＩＬ２／ＩＬ２Ｒ系统的关系。方法　分别采用ＥＬＩＳＡ法、１２５ＩＲＩＡ法及免疫荧光法对５０ 例胃癌患者手术前后外周血中ＩＬ２、ｓＩＬ２Ｒ、ＰＧＥ２ 水平及ＣＤ２５ 表达进行检测。结果　胃癌患者手术前后外周血中ＩＬ２ 水平及ＣＤ２５ 表达均低于对照组,而ｓＩＬ２Ｒ与ＰＧＥ２ 水平均高于对照组;切除肿瘤后ＩＬ２ 水平及ＣＤ２５ 表达较术前升高,而ｓＩＬ２Ｒ及ＰＧＥ２ 水平较术前下降;６ 例术后发生肿瘤转移或复发的患者中,再次出现ＩＬ２ 水平及ＣＤ２５ 表达下降,而ｓＩＬ２Ｒ及ＰＧＥ２ 水平上升,胃癌患者术前ＩＬ２ 水平与术前ＰＧＥ２ 水平呈显著负相关,术前ｓＩＬ２Ｒ水平与ＩＬ２ 水平亦呈显著负相关。结论　ＰＧＥ２ 与ｓＩＬ２Ｒ 参与了胃癌患者术前存在的免疫抑制过程。非甾体抗炎药（ＮＳＡＩＤ）与外源性ＩＬ２ 联合应用以预防胃癌转移或复发理论上具有可行性。     

膀胱移行细胞癌血管内皮生长因子的表达及临床意义

目的探讨血管内皮生长因子与膀胱癌浸润及复发的关系。方法应用ＬＳＡＢ免疫组织化学技术检测４０例膀胱移行细胞癌血管内皮生长因子（ＶＥＧＦ）的表达。结果膀胱癌细胞ＶＥＧＦ的表达率为５５％（２２／４０）,浸润性癌组ＶＥＧＦ的表达显著高于表浅性癌组（Ｐ＜０．０１）,有淋巴结转移癌组显著高于无转移癌组（Ｐ＜０．０５）,复发性癌组较初发性癌组差异有显著性（Ｐ＜０．００１）。结论ＶＥＧＦ可作为判断膀胱癌生物学行为的指标之一。     

血小板衍化内皮细胞生长因子和血管内皮生长因子在肝细胞癌和门静脉癌栓中的表达

目的 探讨肝细胞癌（ＨＣＣ）门静脉癌栓的形成机制。方法 采用Ｎｏｒｔｈｅｒｎ印迹分析法,对手术切除的２８例ＨＣＣ和１８例门静脉癌栓标本中血小板衍化内皮细胞生长因子（ＰＤ－ＥＣＧＦ）ｍＲＮＡ和血管内皮生长因子ｍＲＮＡ的表达水平进行相对定量研究。结果 ＰＤ－ＥＣＧＦｍＲＮＡ在门静脉癌栓、ＨＣＣ和癌周肝组织中的表达率分别为７７．８％、６７．８％６ ３５．７％,ＶＥＧＦｍＲＮＡ则分别为８８．９％、７５．０     

High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies

Background Radiofrequency ablation (RFA) is a recently developed treatment for hepatocellular carcinoma (HCC). Thus far, the prognostic impact of tumor biomarkers has not been evaluated in this treatment. High serum level of vascular endothelial growth factor (VEGF) has been shown to predict microscopic vascular invasion and metastasis in HCC. This study investigated the prognostic significance of pre-treatment serum VEGF level in patients with HCC undergoing RFA treatment. Methods Serum VEGF levels were measured using enzyme-linked immunosorbent assay in 120 patients with HCC undergoing RFA, and in 15 healthy controls. Serum VEGF levels were correlated with clinicopathological features of the HCC patients. The prognostic significance of serum VEGF levels was assessed by univariate and multivariate analyses. Results The median serum VEGF level in the HCC patients was 240 pg/mL (range 17–1162), significantly higher than that of healthy controls (p = .024). The serum VEGF levels were significantly correlated with platelet counts (r = .487, p < .001) but not other clinicopathological features. Patients with serum VEGF level > 240 pg/mL had worse overall and recurrence-free survival compared with those with serum VEGF level > 240 pg/mL (p = .005 and .002, respectively). By multivariate analysis, serum VEGF level was a significant prognostic factor of both overall and recurrence-free survival. Conclusions High pre-treatment serum VEGF levels predict poor prognosis after RFA of HCC. This study highlights the importance of tumor biomarker as a prognostic predictor in ablative therapy for HCC, which has an intrinsic problem of unavailability of histopathological prognostic features.     

Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma

BACKGROUND: Vascular endothelial growth factor (VEGF) and endostatin stimulate and inhibit tumour angiogenesis respectively. Recent studies have demonstrated the prognostic value of serum levels of both VEGF and endostatin in patients with various types of cancer. Their significance in patients with hepatocellular carcinoma (HCC) remains unclear. METHODS: Serum VEGF and endostatin levels were measured by enzyme immunoassay in 108 patients with HCC before surgical resection and in 20 healthy controls. Preoperative serum VEGF and endostatin levels were correlated with clinicopathological features and long-term survival. RESULTS: Serum VEGF levels in patients with HCC were significantly higher than those in controls, but serum levels of endostatin were similar in the two groups. High serum levels of VEGF, but not endostatin, were significantly associated with venous invasion and advanced tumour stage. Patients with a serum VEGF level higher than median (over 245.0 pg/ml) had significantly worse overall and disease-free survival than those with a lower level (P = 0.012 and P = 0.022 respectively). On multivariate analysis, serum VEGF level was an independent prognostic factor (hazard ratio 1.86 (95 per cent confidence interval 1.10 to 3.92); P = 0.032). Serum endostatin levels did not have significant prognostic influence on overall or disease-free survival. CONCLUSION: A high serum level of VEGF is a predictor of poor outcome after resection of HCC. Serum VEGF, but not endostatin, may be a useful prognostic marker in patients with HCC.     

Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study

OBJECTIVE: To evaluate the correlation between serum vascular endothelial growth factor (VEGF) level and the clinicopathologic features in patients with hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA: VEGF is an important angiogenic factor regulating tumor angiogenesis. A high serum VEGF level has been shown to be associated with tumor progression and metastasis in several human cancers, but its significance in HCC is unclear. The correlation between serum VEGF level and tumor pathologic features in patients with HCC has not been studied before. METHODS: Preoperative serum samples and tumor specimens were prospectively collected in 100 patients undergoing resection of HCC. Serum VEGF level was measured by enzyme-linked immunosorbent assay, and tumor VEGF expression was assessed by immunohistochemical study. Histopathologic examination was performed by a pathologist without prior knowledge of the serum VEGF level or tumor VEGF expression. RESULTS: Preoperative serum VEGF levels ranged from 15 to 1,789 pg/mL (median 269). When serum VEGF levels were compared between groups categorized by different clinicopathologic variables, significant correlation was found between a high serum VEGF level and absence of tumor capsule, presence of intrahepatic metastasis, presence of microscopic venous invasion, and advanced stage. There was a positive correlation between the serum VEGF level and tumor expression of VEGF as well as platelet count. When the 75th percentile serum VEGF level (500 pg/mL) was used as a cutoff level, the frequency of venous invasion in patients with a high serum VEGF level was significantly greater compared with patients with a low serum VEGF level. By multivariate analysis, a serum VEGF level of more than 500 pg/mL and tumor size more than 5 cm were independent preoperative factors predictive of microscopic venous invasion. During a median follow-up of 11.6 months, 48% of patients with a serum VEGF level of more than 500 pg/mL and 27% of those with a serum VEGF level of 500 pg/mL or less developed postoperative recurrence. CONCLUSIONS: These results show that a high preoperative serum VEGF level is a predictor of microscopic venous invasion in HCC, suggesting that the serum VEGF level may be useful as a biologic marker of tumor invasiveness and a prognostic factor in HCC.     

Prognostic Significance of Vascular Endothelial Growth Factor,Basic Fibroblast Growth Factor,and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After Surgery

Background: Hepatocellular carcinoma (HCC) is a hypervascular malignancy. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and angiogenin (ANG) are important angiogenic factors of neoangiogenesis. This study investigated the predictive value of serum VEGF, bFGF, and ANG in tumor recurrence, disease-free survival (DFS), and overall survival (OS) in HCC patients.Methods: Preoperative serum VEGF, bFGF, and ANG were measured in 98 patients with resectable HCC and in 15 healthy controls. The median follow-up time was 43 months.Results: Preoperative serum VEGF was increased in patients with resectable HCC compared with healthy controls (P < .05). Increased serum VEGF was correlated with tumor recurrence (P = .001). Univariate analysis showed that serum VEGF, tumor-node-metastasis stage, tumor size and number, macroscopic portal vein invasion, and microscopic vascular invasion were correlated with OS and DFS. Serum bFGF and ANG were not associated with survival. Multivariate analysis showed that serum VEGF was the most significant predictor of DFS (relative risk, 2.35; 95% confidence interval, 1.26–4.39; P = .007) and OS (relative risk, 3.44; 95% confidence interval, 1.81–6.57; P < .001) in HCC patients after surgical resection.Conclusions:Preoperative serum VEGF is a significant independent predictor of tumor recurrence, DFS, and OS in patients with resectable HCC.     

基质金属蛋白酶-9和血管内皮生长因子与原发性肝癌侵袭转移关系研究

目的　探讨原发性肝癌中MMP 9和VEGF基因的表达 ,探讨其与原发性肝癌侵袭转移的关系。方法　采用逆转录 聚合酶链式反应 (RT PCR)技术 ,检测 41例原发性肝癌手术切除肿瘤组织、癌旁组织标本的MMP 9和VEGF基因表达。结果　肝癌组织和癌旁 1cm、5cm组织中分别有 70 7%、48 9%、41 5 %MMP 9表达阳性和 75 6%、5 3 7%、46 3 %VEGF表达阳性 ,癌组织的MMP 9和VEGF表达水平显著高于癌旁 5cm组织 (P <0 0 1) ,癌组织与癌旁 1cm组织MMP 9和VEGF表达水平无显著性差异。癌组织中MMP 9和VEGF的表达水平与有无包膜、门静脉癌栓有显著性差异 (P <0 0 5 )。MMP 9与复发、AFP阳性有显著性差异 (P <0 0 5 ) ,而VEGF与之无差异。结论　MMP 9和VEGF基因的过度表达与肝癌侵袭转移密切相关 ,MMP 9可作为判断预后的指标     

前列腺癌患者外周血Matriptase和VEGF检测及其临床意义

目的 联合检测前列腺癌患者外周血中Matriptase和血管内皮生长因子(vascular endothelial growth factor,VEGF)的表达、与前列腺癌临床参数的关系,探讨其临床意义。方法 采用酶联免疫吸附ELISA法检测47例前列腺癌（其中20例远处转移）、45例良性前列腺疾病（20例前列腺炎、2...     

血清lncRNA HULC水平与乙型肝炎病毒相关性肝细胞癌患者临床特征及预后的关系

背景与目的：长链非编码RNA HULC（lncRNA HULC）在肝癌中特异性高表达,是肝癌重要的肿瘤标志物。本研究探讨血清lncRNA HULC水平与乙型肝炎病毒相关性肝细胞癌（乙肝相关性肝癌）患者临床特征及预后的关系。 方法：收集2012年6月—2017年9月30例接受手术治疗的乙肝相关性肝癌患者血清与手术标本。用qRT-PCR检测患者血清lncRNA HULC的含量,免疫组织化学法检测患者癌组织中肿瘤侵袭转移相关标志物VEGF、MMP-2、E-cadherin的表达。分析患者血清lncRNA HULC水平与患者临床病理因素、侵袭转移相关标志物表达及术后预后的关系。 结果：患者血清lncRNA HULC相对水平范围为2.6~9.5,以中位值5.0为界,将患者分为高lncRNA HULC组（12例）与低lncRNA HULC组（18例）。统计分析结果显示,低lncRNA HULC组病理高分化比例高于高HULC组;高lncRNA HULC组III~IV期比例高于低lncRNA HULC组;HULC-L组肝内转移与远处转移例数均比例低于HULC-H组肝癌患者;高lncRNA HULC组肝癌切除术后复发比例高于低lncRNA HULC组肝癌患者,差异均有统计学意义（均P<0.05）。免疫组化结果显示,与低lncRNA HULC组比较,高lncRNA HULC组患者肝癌组织中促肿瘤侵袭转移蛋白VEGF、MMP-2的阳性表达增加,而抑制促肿瘤侵袭转移蛋白E-cadherin的阳性表达明显减少。Kaplan-Meier法分析结果显示,高lncRNA HULC组患者生存率低于低lncRNA HULC组患者,且肝癌切除术后复发率高于低lncRNA HULC组肝癌患者（均P<0.05）。Cox比例风险回归分析结果显示,术前血清HULC水平是乙肝相关性肝癌患者预后的独立影响因素（OR=1.769,P=0.045）。 结论：血清lncRNA HULC水平与乙肝相关性肝癌患者恶性临床特征密切相关,高血清lncRNA HULC水平的乙肝相关性肝癌患者预后不良。     

Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors

OBJECTIVE: Gliomas account for most primary brain tumors in adults, and survival correlates with the grade and vascularity of the tumor. The degree of tumor-related angiogenesis seems to be a significant predictor of tumor progression, recurrence, and metastatic spread in a variety of malignant diseases, including brain tumors. Our study's objective was to quantify the levels of two angiogenic factors, basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), in the cerebrospinal fluid (CSF) and serum of patients with gliomas and to correlate these levels with tumor grade, vascularity, and overall survival. METHODS: Twenty-six patients with the diagnosis of cerebral glioma (19 high-grade, 7 low-grade) comprised the study group. Ten patients with communicating hydrocephalus served as controls. Levels of VEGF and bFGF in the CSF and serum were determined using enzyme-linked immunosorbent assay analysis. Tumor vascularity was graded qualitatively using immunohistochemical staining for CD34. Nonparametric statistical techniques were used for data analysis. RESULTS: Median levels of bFGF and VEGF in the CSF were significantly higher in patients with high-grade glioma as compared with patients with low-grade glioma or hydrocephalus (bFGF levels, 52, 26, and 24 ng/ml, respectively, P < 0.0001; VEGF levels, 17.6, 7.2, and 8.3 ng/ml, respectively, P < 0.005). A significant correlation was found comparing CSF levels of bFGF with levels of VEGF (P < 0.001). The levels of the angiogenic factors in the CSF correlated with the degree of tumor vascularity and were adversely associated with patient survival. Serum levels of the angiogenic factors showed no correlation to tumor grade, vascularity, or survival. CONCLUSION: Our data suggest that CSF levels of bFGF and VEGF may serve as an additional marker for tumor grading and vascularity and may help predict survival.     

Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients

Vascular endothelial growth factor (VEGF) is used to evaluate the angiogenic activity in breast carcinoma. Nitric oxide (NO) and insulin-like growth factor-I (IGF-I) are also implicated in breast tumorigenesis, including angiogenesis. We measured serum VEGF, IGF-I and nitrate+nitrite levels in 38 patients with metastatic and 23 with nonmetastatic breast cancer and in 16 controls. Serum VEGF and IGF-I levels were higher in patients with metastatic disease than in those with nonmetastatic disease or in controls (P<0.001). Serum nitrate+nitrite levels were higher in patients with metastatic and nonmetastatic disease than in controls (P<0.001). Patients with visceral metastasis and local metastasis had higher serum VEGF and nitrate+nitrite levels than patients with bone metastasis (P<0.05). In the metastatic disease group, there was a positive correlation between serum VEGF levels and nitrate+nitrite levels (r=0.436, P<0.05). Within the group with nonmetastatic disease, premenopausal patients had higher serum IGF-I levels than did postmenopausal patients (P<0.001). NO may involve an angiogenic process that is stimulated by VEGF in breast carcinoma. Larger studies are required to clarify these suggestions.     

乳腺癌患者血清和肿瘤组织VEGF表达与临床预后的关系

目的探讨乳腺癌患者血清和肿瘤组织中血管内皮细胞生长因子（VEGF）的表达以及与临床预后的关系。方法以44例乳腺癌患者、13例乳腺良性疾病患者和40例正常人为研究对象，分别采用酶联免疫吸附法（ELISA）检测其血清VEGF水平，采用免疫组化LSAB法检测其组织中VEGF、雌激素受体（ER）和原癌基因C-erbB-2蛋白的表达，并分析其与临床预后因素如淋巴结转移情况及临床分期的关系。结果乳腺癌组血清和组织中VEGF表达水平（113．88pg／ml，20723．99）均明显高于乳腺良性疾病组（55．79pg／ml，3594．74），P〈0．001，而乳腺良性疾病组与正常对照组（41．30pg／ml，-）比较差异无统计学意义（P〉0．05）；且血清和组织中VEGF的表达呈正相关（r=0．48，P〈0．01）。有淋巴结转移者血清和组织中VEGF的表达水平（129．60pg／ml，28506．82）明显高于无淋巴结转移者（80．80pg／ml，14656．73），P〈0．01；血清和组织中VEGF的表达与肿瘤的临床分期有关（P〈0．01），但与患者年龄和肿瘤大小无关（P〉0．05）。乳腺癌患者血清和组织中VEGF表达水平与组织中ER表达呈负相关（r=-0．45，P〈0．05），与C-erbB-2表达呈正相关（r=0．48，P〈0．01）。结论乳腺癌患者血清和肿瘤组织中VEGF表达呈正相关，且与其临床预后有关，可作为乳腺癌患者预后判断的重要参考指标之一。